Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical research and therapy development.

Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge technologies in individual products and fully integrated platforms. Allele utilizes proprietary non-integrating cellular reprogramming methods to enable drug discovery and cell therapy, including human and non-human primate iPS cells, GMP-grade human iPS cells and their derivatives, and differentiated cell types.  With additional expertise in genome modification and cell-based sensors/reporters, Allele provides advanced cell and assay development solutions. Allele also has developed a wide variety of reagents including superior fluorescent proteins, highly efficient luciferase assay substrates, genotyping kits, and camelid antibodies. The company has also been a leader in the RNAi field with its patents in Pol III promoter-driven siRNA, shRNA, and miRNA.



If you are committed to making a significant difference within the scientific community, and believe in career advancement; we invite you to learn more about our business groups, our products and plans for the future. Please Email: employment@allelebiotech.com


  • 1999 - Company founded.
  • 2000 - Established R&D facilities.  
  • 2001 - Received funding through 3 NIH SBIR grants.
  • 2001 - Launched oligo synthesis service.
  • 2001 - Filed for the first Pol III driven RNAi patent.
  • 2002 - Patent-pending RNAi technology developed into LineSilence Kits.
  • 2002 - LineSilence Kits launched as the first DNA-based RNAi system, marketed through Promega.
  • 2003 - Established custom services to carry out CRO projects.
  • 2003 - Received 2 more NIH grants to further develop Allele RNAi platform.
  • 2004 - Developed innovative systems for quantitative RNA detection.
  • 2004 - Initiated the first ever RNAi workshop series in top universities around China through subsidiary company Allele China.
  • 2005 - Became an end user market-oriented business by major expansions in new products, direct sales team, and professional customer service.
  • 2006 - Moved to the Mesa Rim, San Diego facility in an expansion of business.
  • 2006 - Allele launches its first fluorescent protein product.
  • 2007 - Granted the first US patent on DNA-driven RNAi technology.
  • 2007 - Accelerated customer services in the area of antibody gene cloning and cell line establishment for therapeutic companies.
  • 2007 - Sub-licensed Alleleustrous fluorescent proteins to leading drug companies.
  • 2008 - Successfully completed a cancer diagnostics antibody development contract for the National Cancer Institute, NIH in collaboration with AvantGen.
  • 2008 - Second US patent issued on broad use of engineered human and mouse U6 promoter to introduce siRNA or shRNA.
  • 2008 - Acquired Orbigen, Inc. and expanded product line to include about 1,000 antibodies and baculovirus protein expression system, etc.
  • 2009 - Third US patent issued on siRNA and shRNA in the US.
  • 2009 - Introduction of iPSC product line.
  • 2009 - Broad DNA-expressed RNAi patent issued in China
  • 2009 - Publication in PLosOne on RNA splicing regulator that can bind two different RNA targets at a distance or on different molecules.
  • 2009 - Introduction of Chromotek GFP-Trap and other camelid antibody products
  • 2010 - Carried out glycosylated cancer antigen production project for NCI
  • 2010 - Received 3 grants on qualified therapeutics and diagnostics projects
  • 2010 - Received NCI funding on shRNA screening in cancer-related DNA damage repair pathway
  • 2010 - Published original research paper and filed a patent application on photoconvertible fluorescent protein (mClav series).
  • 2011 - Launched a new web-based purchasing system.
  • 2011 - Filed for patents on: enzyme-based ratio enhancement for detection of genetic diseases using maternal blood DNA; using fluorescent proteins for skin protection
  • 2011 - Expanded iPS product line to include in vitro transcription template for introducing reprogramming or directed differentiation factor mRNAs
  • 2011 - Received and successfully executed a contract from the National Institute on Drug Abuse /NIH to develop novel technologies for isolating camelid antibodies
  • 2012 - Founded the Scintillon Institute for bioengineering and bioimaging with Dr. Nathan Shaner for nonprofit research with long-term basic research projects for the advancement of science and benefits of human society.
  • 2012 - Purchased a two-story building and are planning to convert it into a class A, GMP ready molecular and cell biology laboratory to support R&D and new stem cell business.
  • 2012 - Developed novel mRNA-based reprogramming technologies, an effort led by Dr. Luigi Warren, which is accepted for publication at Nature’s Scientific Reports and is the subject of a new patent application.
  • 2012 - Published an original research paper describing a novel adipogenesis regulatory factor AFRO (or ADIRF for Adipogenesis Regulatory Factor designated by HUGO after our publication)
  • 2013 - Published the brightest monomeric fluorescent protein mNeanGreen in Nature Methods from a collaboration with the Scintillon Institute researchers lead by Dr. Nathan Shaner
  • 2013 – Launched the Superresolution for every lab campaign, with a web portal to provide information and resources: superresolution.allelebiotech.com, and a new distribution model, http://www.allelebiotech.com/categories/Fluorescent-Proteins/Sublicensing/
  • 2014 - Dr. Jiwu Wang co-authored in a Nature Medicine article on using iPSCs for mitochondrial cardiomyopathy modeling with researchers with collaborators at Harvard led by Drs. Pu, Church, Chien, Keller, Parker etc.
  • 2014 – A publication by an ACT/Ocata team in Stem Cell Reports (Dr. Jiwu Wang as a co-author) showed that Allele’s mRNA-iPSCs differentiate well in a large scale platelet production process.
  • 2014 – Received VC funding for expanding stem cell cGMP production and custom banking. Yuan Group and Yifang are the leading VC firms in this round.
  • Received 2 NIH SBIR grants on developing an all RNA platform for CRISPR genome modification (NIGMS) and nano-antibodies (nAb) against mRNA modification groups (NIDA).
  • 2015 - Purchased the second building, of 18,000 square feet, with cleanroom setup to accommodate Allele’s cGMP iPSC and stem cell derived tissues cells for future therapies.
  • 2015 – Close the tranch 2 investment for business expansion. Establish facilities for new laboratory spance, animal care, and high throughput drug screening center for Allele and Scintillon Institute.
  • 2015 – Recived an NIH grant (NIA) to develop nano-antibodies (nAb) against Ab in treating Alzheimer’s disease.
  • 2015 – Formed formal drug development venture with high content screening company Vala Sciences through investment and formally launched joint drug development service including kinetic imaging and histology analysis.